Coenzyme M

Generic Name: Coenzyme M

Brand Names: Uromitexan

Drug Type: Small Molecule

Chemical Formula: C_₂H_₆O_₃S_₂

CAS Number: 3375-50-6

Unique Ingredient Identifier: VHD28S0H7F

Background: Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication: Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions: Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide

Clinical Trials

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Early Phase 1

Not yet recruiting

Conditions: CNS Embryonal Tumor
CNS, Medulloblastoma
Atypical Teratoid Rhabdoid Tumor
Medulloblastoma, Childhood
Medulloblastoma, Group 3
Medulloblastoma, Group 4
Pineoblastoma
Embryonal Tumor With Abundant Neuropil and True Rosettes
Ependymoblastoma
Medulloepithelioma

Interventions: Drug: Cytarabine IT
Drug: hydrocortisone
Drug: Cisplatin
Drug: Vincristine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Mesna
Drug: Filgrastim
Drug: carboplatin
Drug: Thiotepa
Drug: Topotecan IT
Drug: Tamoxifen
Drug: ISOtretinoin
Drug: Celecoxib
Drug: etoposide phosphate
Drug: Temozolomide

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: C17 Council

Target Recruit Count: 15

Registration Number: NCT06942039

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Device: CD19-CD22 CAR T cell infusion

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 30

Registration Number: NCT06777979

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Biological: CD19-CAR T cell Infusion

First Posted Date: 2025-02-26

Last Posted Date: 2025-05-15

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 25

Registration Number: NCT06847269

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

CER-1236 in Patients With Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: AML
Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: CER-1236
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2025-02-19

Last Posted Date: 2025-04-30

Lead Sponsor: CERo Therapeutics Holdings, Inc.

Target Recruit Count: 18

Registration Number: NCT06834282

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1

Suspended

Conditions: Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Non-Active Secondary Progressive Multiple Sclerosis
Non-Active SPMS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Demyelinating Diseases
Immune System Diseases

Interventions: Drug: IDP-023
Drug: Ocrelizumab
Drug: Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2024-11-07

Last Posted Date: 2025-04-30

Lead Sponsor: Indapta Therapeutics, INC.

Target Recruit Count: 34

Registration Number: NCT06677710

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States

and more 2 locations

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Phase 2

Recruiting

Conditions: Splenomegaly
Myelofibrosis

Interventions: Drug: Ruxolitinib
Procedure: Allogeneic Stem Cell Transplantation
Drug: Levetiracetam
Drug: Eltrombopag
Drug: Busulfan
Drug: Romiplostim
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2024-04-03

Last Posted Date: 2025-05-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06345495

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Phase 1

Recruiting

Conditions: ALL, Childhood
MDS
AML, Childhood
Hematologic Malignancy
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: CD70-CAR T cell infusion (Autologous)
Drug: Mesna

First Posted Date: 2024-03-22

Last Posted Date: 2024-12-17

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT06326463

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Efficacy & Safety for LN144 with Pembrolizumab with High Risk Stage IIIb-dResectable Melanoma

Phase 1

Recruiting

Conditions: Stage IIID Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma

Interventions: Biological: LN-144
Drug: Cyclophosphamide
Drug: Mesna
Drug: Fludarabine
Biological: Interleukin-2 (IL-2)
Drug: Pembrolizumab

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-05

Lead Sponsor: James Isaacs, MD

Target Recruit Count: 12

Registration Number: NCT06190249

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1

Recruiting

Conditions: Relapsed Multiple Myeloma
Multiple Myeloma
Blood Cancer
Relapsed Non-Hodgkin Lymphoma
Refractory Multiple Myeloma
NHL
Refractory Non-Hodgkin Lymphoma

Interventions: Drug: IDP-023
Drug: Cyclophosphamide
Drug: Interleukin-2
Drug: Rituximab
Drug: Daratumumab
Drug: Fludarabine
Drug: Mesna
Drug: Isatuximab

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-30

Lead Sponsor: Indapta Therapeutics, INC.

Target Recruit Count: 128

Registration Number: NCT06119685

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States

and more 9 locations

Siplizumab for Sickle Cell Disease Transplant

Phase 1

Recruiting

Conditions: Anemia, Sickle Cell

Interventions: Drug: Siplizumab
Procedure: Exchange Transfusion
Procedure: Total Body Irradiation
Procedure: Stem Cell Infusion
Drug: Cyclophosphamide 50mg
Drug: Mesna
Drug: Sirolimus Oral Tablet
Drug: Rituximab or Biosimilar

First Posted Date: 2023-10-12

Last Posted Date: 2025-02-13

Lead Sponsor: Columbia University

Target Recruit Count: 18

Registration Number: NCT06078696

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy